Outcomes of autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma refractory to first line chemoimmunotherapy

Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). Anthracycline and rituximab-based combination frontline chemoimmunotherapy is highly active and will cure 50-60% of patients.1,2 Relapsed/refractory disease is treated with salvage chemotherapy followed by autologous hematopoietic cell transplantation (autoHCT) in patients with chemosensitive disease, and chimeric antigen receptor (CAR) modified T-cells in patients with refractory disease.3,4

Source: Biology of Blood and Marrow Transplantation - September 15, 2020 Category: Hematology Authors: Susan Bal, Luciano J Costa, Craig Sauter, Carlos Litovich, Mehdi Hamadani Source Type: research